Table 2

Previous studies examining clinical features of myeloid sarcoma.

TotalDe novoSimultaneous haematological disordersPrevious haematological disorders
Our study4526 (6 AML, 1 MDS-MPN)7 (7 AML)12 (4 AML, 4 MDS, 3 MPN, 1 MDS-MPN-myelofibrosis)
Pileri et al119225 (2 AML)32 (26 AML, 1 idiopathic myelofibrosis, 5 MDS)35 (12 AML, 14 MPN, 9 MDS)
Kawamoto et al341313537 (37 AML)59 (31 MDS-MPN-CML, 28 AML)
Al-Khateeb et al4821813 (1 CML-blastic phase, 12 AML)
Chen et al4920119 (14 AML, 4 CML, 1 MDS with AML)
Ullman et al366323 (5AML)2713 (10 MDS-MPN, 3 CML with blastic crisis)
Claerhout et al18721922 (15 AML, 2 MPN, 2 MDS, 3 MDS-MPN)31 (11 AML, 9 AML had arisen from MPN, 8 AML arisen from MDS, 3 AML arisen from MDS-MPN)
Wang and Li2339149 (8 AML, 1 CML)8 (7 AML, 1 MDS)
Zhou et al5033412 (12 AML)17 (14 AML, 1 JMML, 1 atypical CML, 1 MDS-MPN)
  • AML, acute myeloid leukaemia; CML, chronic myeloid leukaemia; JMML, juvenil myelomonocytic leukaemia; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.